AMILORIDE FOR ERADICATION OF BURKHOLDERIA DOLOSA

点击翻译按钮获取中文摘要

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. Primary Objective: Determination of the ability of multiple doses of amiloride solution for inhalation (ASI) and tobramycin solution for inhalation (TSI) to eradicate Burkholderia dolosa respiratory tract infection in patients with cystic fibrosis. Secondary Objectives: 1. Determination of the safety and tolerability of multiple doses of ASI and TSI in patients with cystic fibrosis and Burkholderia dolosa respiratory tract infection. 2. To obtain evidence of efficacy of multiple doses of ASI and TSI in patients with cystic fibrosis and Burkholderia dolosa respiratory tract infection as reflected in a change in pulmonary function, expectorated sputum bacterial colony counts, incidence of pulmonary exacerbations, weight gain, quality of life scores, and inflammatory markers.